The study was undertaken to determine the antagonism of the AP1700 on the development of nalbuphine-induced tolerance and physical dependence. AP1700 is an oriental drug preparationcomposed of 5 natural products and is known to have antinarcotic action with an oral dose of 250 mg/kg in rats. AP1700 ...
The study was undertaken to determine the antagonism of the AP1700 on the development of nalbuphine-induced tolerance and physical dependence. AP1700 is an oriental drug preparationcomposed of 5 natural products and is known to have antinarcotic action with an oral dose of 250 mg/kg in rats. AP1700 significantly inhibits the development of antinarcotic action with an oral dose of 250 mg/kg in rats. AP1700 significantly inhibits the development of nalbuphine-induced physical dependence but does not the tolerance. Mitogen-activated protein kinase, which include extracellular signal-regulated kinase (ERK), p38 and c-Jun N-terminal kinase (JNK)/stress-activated protein kinase (SAPK) play critical roles in cell growth and survival and drug abuse. The level of pCREB was elevated in the hippocampus by the chronic treatment with nalbuphine, however, the elevation of pCREB was not inhibited by the AP1700 co-treatment. Interestingly, the level of pERK was decreased in the co-treatment with nalbuphine and AP1700 on the cortex and striatum. However, the level of nNOS and NR1 was not modulated by the treatment with nalbuphine or AP1700 on the cortex, hippocampus and striatum in the rat brain. These results suggest that the AP1700 could be used to ameliorate the nalbuphine withdrawal symptoms.
The study was undertaken to determine the antagonism of the AP1700 on the development of nalbuphine-induced tolerance and physical dependence. AP1700 is an oriental drug preparationcomposed of 5 natural products and is known to have antinarcotic action with an oral dose of 250 mg/kg in rats. AP1700 significantly inhibits the development of antinarcotic action with an oral dose of 250 mg/kg in rats. AP1700 significantly inhibits the development of nalbuphine-induced physical dependence but does not the tolerance. Mitogen-activated protein kinase, which include extracellular signal-regulated kinase (ERK), p38 and c-Jun N-terminal kinase (JNK)/stress-activated protein kinase (SAPK) play critical roles in cell growth and survival and drug abuse. The level of pCREB was elevated in the hippocampus by the chronic treatment with nalbuphine, however, the elevation of pCREB was not inhibited by the AP1700 co-treatment. Interestingly, the level of pERK was decreased in the co-treatment with nalbuphine and AP1700 on the cortex and striatum. However, the level of nNOS and NR1 was not modulated by the treatment with nalbuphine or AP1700 on the cortex, hippocampus and striatum in the rat brain. These results suggest that the AP1700 could be used to ameliorate the nalbuphine withdrawal symptoms.
* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.
가설 설정
Western blot analysis of protein levels suggests that signal transduction system was not solely attributable to the nalbuphine-induced withdrawal syndrome. We hypothesize that the inhibitory effects of AP1700 on nalbuphine- induced physical dependence are closely related to the modulation of CREB (cyclic AMP response element-binding) protein expression.
제안 방법
Additional groups of rat that had received the same nalbuphine and AP1700 as described in the development of nalbuphine tolerance were used in this experiment. The inhibition of naloxone-induced withdrawal syndrome in nalbuphine-dependent rat was estimated by the observation of the withdrawal syndrome by naloxone 10 ㎎/㎏ (i.
Rats were received nalbuphine (10 ㎎/㎏, i.p.) and/or AP1700 (250 ㎎/㎏, p.o.) for 6 days, and were challenged with naloxone (10 ㎎/㎏, i.p.) 24h after the final injection of nalbuphine. Numbers denote the number of rats showing positive signs over the total number of rats tested for 30 min after injection of naloxone.
AP1700 250 ㎎/㎏ were administered orally to rat Ihr prior to the injection of nalbuphine. The test of nalbuphine analgesia was estimated at 0, 30, 60, 90 minutes for 6days by tail flick methods (n=10). The inhibitory effects of AP1700 on the development of nalbuphine-induced tolerance were shown on day 1 (A), day 3 (B), and day 5 (C).
This study was undertaken to determine the antagonism of nalbuphine analgesia by AP1700, the inhibitory effects of AP1700 on the development of nalbuphine tolerance and physical dependence in rats, and the hepatic glutathione contents which are closely related to the degree of detoxification of mor- phinone, a novel metabolite of morphine (Nagamatsu et W., 1983). Also, we determined the inhibitory effect of AP1700 on the modulation of MAPK, NMDA receptor (NR1 subunit), nNOS expression in the rat brain regions.
대상 데이터
Rats (Sprague-Dawley, male) weighing 250-280g in a group of 10, were used in all experiments. The AP1700 is composed of 5 natural products (Sulfur precipitatum, Aconiti Tuber, Atractyloids Rhizoma Alba, cinnamon, Lonicerae Flos) was dissolved in distilled water and administered orally.
데이터처리
The data were expressed as mean + S.E. The differences in the means for different responses in different treatment groups were analyzed by the Student, s t-test.
성능/효과
In our experimental results, the level of pCREB was not significantly modulated by the co-treatment with nalbuphine and AP1700 although the level was decreased than that of API700 alone. Furthermore the level of NR1 and nNOS was not elevated by the treatment with nalbuphine.
후속연구
, 2004). However, it needs some more experiment to explain the correlation with antagonism of dependence and pERK suppression. It could be presumed that AP1700 ameliorated the drug abuse to inhibit the psychological rewarding via downregulation of pERK expression as well as inhibit the physical dependence.
참고문헌 (28)
Belcheva, M.W., Vogel, Z., Ignatova, E., Avidor-Reiss, T., Zippel, R., Levy, R, Young, E.C., Barg, I. and Coscia, C.J. (1998). Opioid modulation of extracellular signal-regulated protein kinase activity is Ras-dependent and involves $G{\beta}{\gamma}$ subunits. J. Neurochem. 70, 635-645
Berhow, M.T., Hiroi, N. and Nestler, E.J. (1996). Regulation of ERK, part of the neurotropin signal transduction cascade, in the rat meso limbic dopamine system by chronic exposure to morphine or cocaine. J. Neurosci. 16, 4707-4715
Chen, J.C., Smith, E.R., Cahill, M., Cohen, R. and Fishman, J.R. (1992). The opioid receptor binding of pentazocine, morphine, fentanyl, butorphanol and nalbuphine. Life Sci. 52, 389-396
Childers, S.R. (1991). Opioid receptor-coupled second messengers. Life Sci. 48, 1991-2003
Cuellar, B., Fernandez, A.P., Lizasoain, I., Moro, M.A., Lorenzo, P., Bentura, M.L., Rodrigo, J. and Leza, J.C. (2000) Up-regulation of neuronal NO synthase immunoreactivity in opiate dependence and withdrawal. Psychopharmacology (Berl.) 148, 66-73
Kim, D.S., Lim, H.K, Jang, S. and Oh, S. (2003). Changes of the level of G protein ${\alpha}$ -subunit mRNA by tolerance to and withdrawal from butorphanol. Neurochem. Res. 28, 1771-1778
Koyuncuoglu, H., Dizdar, Y., Aricioglu, F. and Sayin, U. (1992). Efects of MK-801 on morphine physical dependence: attenuation and intensification. Pharmacol. Biochem. Behav. 43, 484-490
Nagamatsu, K., Kido, Y., Terao, T., Ishida, T. and Toki, S. (1982). Protective effect of sulfhydryl compounds on acute toxicity of morphinone. Life Sci. 30, 1121-1127
Nagamatsu, K., Kido, Y., Terao, T., Ishida, T. and Toki, S. (1982). Effect of morphinone on opiate receptor binding and morphine-elicited analgesia. Life Sci. 31, 1451-1457
Nagamatsu, K., Kido, Y., Terao, T., Ishida, T. and Toki, S.(1983). Studies on the mechanism of covalent binding of morphine metabolites to proteins in mouse. Drug Meta. Dispos. 11, 190-194
Nestler, E.J. (1996). Under siege: the brain on opiates. Neuron 16, 897-900
Noda, Y., Yamada, K., Komori, Y., Sugihara, H., Furukawa, H., Nabeshima, T. (1996) Role of nitric oxide in the development of tolerance and sensitization to behavioral effects of phencyclidine in mice. Br. J. Pharmacol. 204, 339-340
Oh, S., Kim, J.I., Chung, M.W. and Ho, I.K. (2000). Modulation of NMDA receptor subunit mRNA in butorphanol-tolerant and - withdrawing rats. Neurochem. Res. 25, 1603-1611
Ozaki, S., Narita, M., Narita, M., Ozaki, M., Khotob, J. and Suzuki, T. (2004). Role of extracellular signal-regulated kinase in the ventral tegmental area in the suppression of the morphine-induced rewarding effect in mice with sciatic nerve ligation. J. Neurosci. 88, 1389-1397
Penning, J.P., Samson, B., Baxter, A.D. (1988). Reversal of epidural morphine-induced respiratory depression and pruritus with nalbuphine. Can. J. Anaesth. 35, 599-604
Rhim, H. and Miller, R.J. (1994). Opioid receptors modulate diverse types of calcium channels in the nucleus tractus solitarius of the rat. J. Neurosci. 14, 7608-7615
Tokuyama, S., Wakabayashi, H. and Ho, I.K. (1996) Direct evidence for a role of glutamate in the expression of opioid withdrawal syndrome. Eur. J. Pharmacol. 295, 123-129
Zhang, Z., Xin, S.M., Wu, G.X., Zhang, W.B., Ma, L. and Pei, G. (1999). Endogenous ${\\delta}$ -opioid and $ORL_1$ receptors couple to phosphorylation and activation of p38 MAPK in NG 108-15 cells and this is regulated by protein kinase A and protein kinase C. J. Neurochem. 73, 1502-1509
※ AI-Helper는 부적절한 답변을 할 수 있습니다.